The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

Inclusion Criteria: * Females, age 18-40 years * BMI ≥ 30 kg/m2 * Diagnosis of polycystic ovary syndrome defined by 2003 Rotterdam criteria as meeting two out of the three below criteria : * Oligomenorrhea or amenorrhea * clinical or biochemical evidence of hyperandrogenism (hirsutism and/or documented upper normal or elevated serum testosterone in the absence of exogenous hormone therapy or Metformin) * documented history of polycystic ovaries on ultrasound examination Exclusion Criteria: * Smoking * Type 1 or Type 2 Diabetes Mellitus, as defined by a fasting glucose of 126 mg/dL or greater at the time of screening visit or the use of anti-diabetic medication * Hypertension, as defined by an untreated seated systolic blood pressure (SBP) greater than 150 mmHg and/or an untreated diastolic blood pressure (DBP) greater than 95 mmHg at the time of screening visit or the use of anti-hypertensive medication * History of reported or recorded hypoglycemia (plasma glucose \< 70 mg/dL) * Pregnancy and/or Breast-Feeding (Negative serum pregnancy test will be confirmed at screening visit and every study visit.) * Surgical menopause, defined as s/p total hysterectomy including bilateral salpingo-oophorectomy * Use of transdermal or oral contraceptive therapy. The use of these contraceptives must be discontinued at least 8 weeks prior to study initiation. * The use of insulin sensitizers, specifically Metformin or thiazolidinediones must be discontinued 8 weeks prior to study initiation. * Anemia defined as hematocrit \<35% at screening visit * Cardiovascular or cerebrovascular disease, including history of myocardial infarction, history of congestive heart failure, history of stroke * Pulmonary Hypertension * Abnormal thyroid hormone levels (TSH), prolactin, or morning 17 hydroxyprogesterone at the time of screening visit * Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<60 * Impaired hepatic function (AST or ALT \> 2 X upper limit of normal range) * Treatment with an investigational drug in the 1 month preceding the study * Allergy to any of the medications used in this protocol * Regular work of a night-shift or unusual schedule which may disrupt circadian rhythm. * Personal or Family History (defined as first degree relative) of Pancreatic Cancer * Personal history of Pancreatitis or known pancreatic lesions * Coagulopathy as defined by history * Regular NSAID use, including but not limited to, naproxen, ibuprofen, and aspirin * Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study * Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study * Any underlying or acute disease requiring regular medication that could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult